|
Interface Biologics develops biomedical polymer technologies that enhance the safety and effectiveness of implantable medical devices (a $90 billion market worldwide) through inhibition of thrombosis, infection control and unique, programmable delivery of pharmaceuticals and biologics.
Interface Biologics is venture capital backed by:
BUSINESS DEVELOPMENT BANK OF CANADA: a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets.
VENGROWTH ASSET MANAGEMENT: one of Canada's premier private equity firms. Since 1982, they have invested over $1.3 billion in almost 200 innovative Canadian companies, building a strong track record of success. VG Partners investment team's breadth of industry experience and collaborative hands-on approach is unparalleled.
COVINGTON CAPITAL: one of Canada’s largest providers of venture capital investment funds. Managing over $400 million in assets, Covington provides Canadians with the ability to access venture capital investment opportunities via their suite of retail venture capital product offerings.
Come and see us at:
BioFinance 2010: April 6-7 2010, Toronto Marriott Eaton Centre, 525 Bay Street
IN3 EUROPE 2010: Paris, France, Marriott Rive Gauche Hotel, April 29-30, 2010
BioContact 2010: October 6-7 2010, Chateau Frontenac, Quebec
For more information please contact Bunmi Dosunmu:
P: 416-673-8401
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
